Compare iShares MSCI Australia ETF (EWA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Viatris Inc — how do they compare? iShares MSCI Australia ETF trades at $30.23, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while iShares MSCI Australia ETF pays none, and iShares MSCI Australia ETF is trading nearer its 52-week high, Viatris Inc nearer its low. Which is the better fit depends on your goals.
| EWA | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $17.86 |
52-Week Low | $24.95 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
